U.S. markets closed

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
95.11-2.39 (-2.45%)
At close: 4:00PM EDT
95.11 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close97.50
Open96.67
Bid80.00 x 900
Ask119.03 x 1100
Day's Range94.97 - 97.28
52 Week Range76.78 - 179.65
Volume230,825
Avg. Volume558,159
Market Cap6.452B
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-5.40
Earnings DateOct 25, 2021 - Oct 29, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est143.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ultragenyx Pharmaceutical Inc.
    RGNX: Lowering target price to $46.00REGENXBIO INC has an Investment Rating of HOLD; a target price of $46.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Benzinga

    Notable Ultragenyx Pharmaceutical Insider Trades $1.14 Million In Company Stock

    Karah Parschauer, EVP And General Counsel at Ultragenyx Pharmaceutical (NASDAQ:RARE), made a large buy and sell of company shares on September 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 8, Karah Parschauer bought 7,336 Ultragenyx Pharmaceutical shares at a price of $54.50 per share, for a total of $399,812. They then sold their shares on the same day in the open market at a price of $100.65 to raise

  • GlobeNewswire

    MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

    NOVATO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Mepsevii® (vestronidase alfa) has been approved for reimbursement by the Agenzia Italiana del Farmaco (Italian Medicines Agency – AIFA) for the treatment of pediatric and adult patients with Mucopolysaccharidosis VII (MPS VII; Sly syndrome). MPS VII

  • GlobeNewswire

    Ultragenyx to Present at Morgan Stanley Healthcare Conference

    NOVATO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President will present at the Morgan Stanley 19th Annual Healthcare Conference on September 14, 2021 at 4:15 PM ET. The live and archived webcast of the presentatio